PR92 antigen in human prostate fluid: elevated levels in prostate cancer

Area of Science:

• Urology
• Biochemistry
• Immunology

Background:

• Prostate cancer diagnosis relies on various markers, but improved specificity and sensitivity are needed.
• Prostatic fluid contains proteins that may serve as diagnostic biomarkers for prostate conditions.

Purpose of the Study:

• To develop and validate an enzyme-linked immunofluorescence assay (EFLA) for quantifying PR92 antigen in prostatic fluid.
• To assess the potential of PR92 antigen as a biomarker for prostate cancer detection.

Main Methods:

• Development of an enzyme-linked immunofluorescence assay (EFLA) using anti-PR92 monoclonal antibody.
• Assay of prostatic fluid samples from 64 patients, including those with prostate cancer, benign prostatic hyperplasia, and a high-risk group.
• Quantification of PR92 antigen in units per microgram (U/microgram) of prostatic fluid proteins.

Main Results:

• PR92 antigen concentrations were significantly higher in men suspected of prostate cancer (227 +/- 42 U/micrograms) compared to those with benign prostatic hyperplasia (87 +/- 23 U/micrograms; P = 0.05).
• 100% of men under 50 had PR92 levels below 25 U/micrograms.
• 91% of men with prostate carcinoma and only 9.5% with benign prostatic hyperplasia showed PR92 levels above 230 U/micrograms.

Conclusions:

• The developed EFLA is a promising tool for determining PR92 antigen levels in prostatic fluid.
• Elevated PR92 antigen concentrations in prostatic fluid may serve as a potential biomarker for prostate cancer.
• Further investigation into PR92 and other prostatic fluid antigens is warranted for improved prostate cancer diagnostics.